CO5070579A1 - Formulaciones de ziprasidona - Google Patents

Formulaciones de ziprasidona

Info

Publication number
CO5070579A1
CO5070579A1 CO99037319A CO99037319A CO5070579A1 CO 5070579 A1 CO5070579 A1 CO 5070579A1 CO 99037319 A CO99037319 A CO 99037319A CO 99037319 A CO99037319 A CO 99037319A CO 5070579 A1 CO5070579 A1 CO 5070579A1
Authority
CO
Colombia
Prior art keywords
ziprasidona
formulations
crystalline ziprasidone
mfi
schizophrenia
Prior art date
Application number
CO99037319A
Other languages
English (en)
Inventor
Frank Robert Busch
Hausberger Angela Carol Gatlin
Rasadi Bijan
Arenson Daniel Ray
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22216447&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO5070579(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of CO5070579A1 publication Critical patent/CO5070579A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Feeding Of Articles By Means Other Than Belts Or Rollers (AREA)
  • Polyamides (AREA)
  • Detergent Compositions (AREA)

Abstract

Composiciones que comprenden partículas de base libre de ziprasidona cristalina o de hidrocloruro de ziprasidona cristalino, que tienen un tamaño medio de partículas inferior a 85 (m, y un vehículo farmacéuticamente aceptable son sustancialmente bioequivalentes y se pueden usar para tratar psicosis, como esquizofrenia. <EMI FILE="99037319_1" ID="1" IMF=JPEG >
CO99037319A 1998-06-15 1999-06-15 Formulaciones de ziprasidona CO5070579A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8922998P 1998-06-15 1998-06-15

Publications (1)

Publication Number Publication Date
CO5070579A1 true CO5070579A1 (es) 2001-08-28

Family

ID=22216447

Family Applications (1)

Application Number Title Priority Date Filing Date
CO99037319A CO5070579A1 (es) 1998-06-15 1999-06-15 Formulaciones de ziprasidona

Country Status (45)

Country Link
US (1) US6150366A (es)
EP (1) EP0965343B1 (es)
JP (2) JP3441676B2 (es)
KR (1) KR100338915B1 (es)
CN (1) CN1307994C (es)
AP (1) AP1216A (es)
AR (1) AR015553A1 (es)
AT (1) ATE240732T1 (es)
AU (1) AU753820B2 (es)
BG (1) BG64691B1 (es)
BR (1) BR9902268A (es)
CA (1) CA2274338C (es)
CO (1) CO5070579A1 (es)
CY (1) CY2003002I1 (es)
CZ (1) CZ297954B6 (es)
DE (1) DE69908021T2 (es)
DK (1) DK0965343T3 (es)
EA (1) EA002223B1 (es)
ES (1) ES2197581T3 (es)
GT (1) GT199900080A (es)
HK (1) HK1024184A1 (es)
HN (1) HN1999000089A (es)
HR (1) HRP990193B1 (es)
HU (1) HU226487B1 (es)
ID (1) ID23546A (es)
IL (1) IL130424A (es)
IS (1) IS2182B (es)
MA (1) MA26647A1 (es)
MY (1) MY121397A (es)
NO (1) NO316713B1 (es)
NZ (1) NZ336271A (es)
OA (1) OA11064A (es)
PA (1) PA8475601A1 (es)
PE (1) PE20000632A1 (es)
PL (2) PL195209B1 (es)
PT (1) PT965343E (es)
RS (1) RS49611B (es)
SG (1) SG77243A1 (es)
SI (1) SI0965343T1 (es)
SK (1) SK286245B6 (es)
TR (1) TR199901379A2 (es)
TW (1) TW590774B (es)
UA (1) UA59383C2 (es)
UY (1) UY25649A1 (es)
ZA (1) ZA993938B (es)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080113025A1 (en) * 1998-11-02 2008-05-15 Elan Pharma International Limited Compositions comprising nanoparticulate naproxen and controlled release hydrocodone
DE60001649T2 (de) * 1999-05-27 2003-08-21 Pfizer Prod Inc Ziprasidonsuspension
US7175855B1 (en) * 1999-05-27 2007-02-13 Pfizer Inc. Ziprasidone suspension
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
AU764453B2 (en) 1999-10-29 2003-08-21 Euro-Celtique S.A. Controlled release hydrocodone formulations
CN101317825A (zh) 2000-10-30 2008-12-10 欧罗赛铁克股份有限公司 控释氢可酮制剂
UY27668A1 (es) * 2002-02-20 2003-10-31 Pfizer Prod Inc Composición de ziprasidona y controles sintéticos
US20040048876A1 (en) * 2002-02-20 2004-03-11 Pfizer Inc. Ziprasidone composition and synthetic controls
US7109198B2 (en) * 2002-05-17 2006-09-19 Duke University Method for treating obesity
WO2004050655A1 (en) * 2002-12-04 2004-06-17 Dr. Reddy's Laboratories Limited Polymorphic forms of ziprasidone and its hydrochloride
US7488729B2 (en) * 2002-12-04 2009-02-10 Dr. Reddy's Laboratories Limited Polymorphic forms of ziprasidone and its hydrochloride salt and process for preparation thereof
US20050143396A1 (en) * 2003-04-11 2005-06-30 Hertero Drugs Limited Novel crystalline forms of ziprasidone hydrochloride
EP2316456B1 (en) 2003-04-29 2017-06-14 Orexigen Therapeutics, Inc. Compositions for affecting weight loss comprising an opioid antagonist and bupropion
CA2528192A1 (en) * 2003-06-03 2005-02-24 Teva Pharmaceutical Industries Ltd Cristalline ziprasidone hcl and processes for preparation thereof
US20050049295A1 (en) * 2003-06-12 2005-03-03 Dr. Reddy's Laboratories Limited Process for the preparation of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1piperazinyl) ethyl)-6-chloro-1, 3-dihydro-2h-indol-2-one hydrochloride (ziprasidone hydrochloride) and its intermediate
CA2537413A1 (en) * 2003-09-02 2005-03-10 Imran Ahmed Sustained release dosage forms of ziprasidone
US7667037B2 (en) * 2003-10-24 2010-02-23 Teva Pharmaceutical Industries Ltd. Processes for preparation of ziprasidone
AU2003285600A1 (en) * 2003-11-28 2005-06-24 Siddiqui Mohammed Jaweed Mukarram Process for the preparing ziprasidone monohydrochloride hydrate
EP1592688A2 (en) * 2003-12-18 2005-11-09 Teva Pharmaceutical Industries Ltd. Polymorphic form b2 of ziprasidone base
WO2005065660A2 (en) * 2003-12-31 2005-07-21 Alpharma, Inc. Ziprasidone formulations
US7713959B2 (en) * 2004-01-13 2010-05-11 Duke University Compositions of an anticonvulsant and mirtazapine to prevent weight gain
EP1734955A2 (en) * 2004-01-13 2006-12-27 Duke University Compositions of an anticonvulsant and an antipsychotic drug for affecting weigt loss
ES2334800T3 (es) * 2004-02-27 2010-03-16 Ranbaxy Laboratories Limited Proceso para la preparacion de ziprasidona.
CN1968692A (zh) * 2004-05-03 2007-05-23 杜克大学 影响体重减轻的组合物
EP1744750A2 (en) * 2004-05-06 2007-01-24 Sandoz AG Pharmaceutical composition comprising hydrophobic drug having improved solubility
CA2467538C (en) * 2004-05-14 2010-08-24 Apotex Pharmachem Inc. New amorphous ziprasidone hydrochloride (5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2h-indol-2-one hydrochloride) and processes to produce the same
US20070237828A1 (en) * 2004-06-11 2007-10-11 Dr. Reddy's Laboratories Limited Ziprasidone Dosage Form
CA2471219A1 (en) * 2004-06-14 2005-12-14 Apotex Pharmachem Inc. Improved preparation of an anhydrate form of 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2h-indol-2-one hydrochloride (ziprasidone hydrochloride)
US9044503B2 (en) * 2004-08-27 2015-06-02 University Of Kentucky Research Foundation Amyloid peptide inactivating enzyme to treat alzheimer's disease peripherally
US20090142404A1 (en) * 2004-08-31 2009-06-04 Pfizer Inc Pharmaceutical dosage forms comprising a low-solubility drug and a polymer
EP2623095A1 (en) * 2004-11-16 2013-08-07 Elan Pharma International Limited Injectable nanoparticulate olanzapine formulations
WO2006085168A2 (en) * 2005-01-07 2006-08-17 Ranbaxy Laboratories Limited Solid oral dosage forms of ziprasidone containing colloidal silicone dioxide
US7749529B2 (en) * 2005-02-08 2010-07-06 Ash Access Technology, Inc. Catheter lock solution comprising citrate and a paraben
CA2593497A1 (en) * 2005-02-11 2006-08-17 Judith Aronhime Amorphous ziprasidone mesylate
ITMI20050346A1 (it) 2005-03-07 2006-09-08 Dipharma Spa Forma solida di ziprasidone cloridrato
CA2500667C (en) * 2005-03-11 2013-01-15 Apotex Pharmachem Inc. Preparation of acid addition salts of ziprasidone and intermediates thereof by solid phase-gas phase reactions
EP1858892A1 (en) * 2005-03-14 2007-11-28 Teva Pharmaceutical Industries Ltd Anhydrous ziprasidone mesylate and a process for its preparation
EP1858891A2 (en) * 2005-03-14 2007-11-28 Teva Pharmaceutical Industries Ltd. Crystalline forms of ziprasidone mesylate
US20080305161A1 (en) * 2005-04-13 2008-12-11 Pfizer Inc Injectable depot formulations and methods for providing sustained release of nanoparticle compositions
US20080193542A1 (en) * 2005-04-13 2008-08-14 Pfizer Inc. Injectable Deopot Formulations and Methods For Providing Sustained Release of Nanoparticle Compositions
PE20061318A1 (es) * 2005-04-22 2006-12-28 Wyeth Corp Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de trastornos psicoticos
DK1884242T3 (da) 2005-05-26 2013-05-06 Dainippon Sumitomo Pharma Co Farmaceutisk sammensætning omfattende lurasidon
JP2008546781A (ja) * 2005-06-20 2008-12-25 エラン・ファルマ・インターナショナル・リミテッド アリール−複素環式化合物を含んでなるナノ粒状及び制御放出の組成物
EA200800092A1 (ru) * 2005-06-20 2008-06-30 Элан Фарма Интернэшнл Лимитед Композиции в виде наночастиц и с контролируемым высвобождением, включающие арил-гетероциклические соединения
EP1951212A2 (en) 2005-11-22 2008-08-06 Orexigen Therapeutics, Inc. Compositions and methods for increasing insulin sensitivity
DK1954241T3 (da) * 2005-11-28 2012-06-18 Orexigen Therapeutics Inc Zonisamid-formulering med vedvarende frigivelse
PL379569A1 (pl) * 2006-04-28 2007-10-29 Pliva Kraków Zakłady Farmaceutyczne Spółka Akcyjna Sposób wytwarzania kompozycji farmaceutycznej zawierającej substancję aktywną ziprasidone lub jego farmaceutycznie dopuszczalną sól zwiększający rozpuszczalność i biodostępność tego leku, kompozycja farmaceutyczna i zastosowanie hydrofilowych substancji pomocniczych
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
EP1889844A3 (en) * 2006-08-02 2008-03-05 Krka Polymorphic forms of ziprasidone sulphates
EP1892243A1 (en) * 2006-08-02 2008-02-27 KRKA, tovarna zdravil, d.d., Novo mesto Polymorphic forms of ziprasidone sulphate salts
KR20090090316A (ko) 2006-11-09 2009-08-25 오렉시젠 세러퓨틱스 인크. 체중 감량 약물을 투여하기 위한 단위 용량 팩키지 및 투여 방법
TW201811315A (zh) 2006-11-09 2018-04-01 美商歐瑞根治療有限公司 層狀醫藥調配物
JP2010527925A (ja) * 2007-05-18 2010-08-19 サイドース・エルエルシー ジプラシドン製剤
EP2197446A4 (en) * 2007-08-31 2012-01-25 Reddys Lab Ltd Dr PREPARATION OF HYDROCHLORIDE OF ZIPRASIDONE MONOHYDRATE
US8410268B2 (en) * 2008-03-11 2013-04-02 Alkem Laboratories Limited Process for the preparation of ziprasidone
CA2725930A1 (en) 2008-05-30 2009-12-30 Orexigen Therapeutics, Inc. Methods for treating visceral fat conditions
DE102008045854A1 (de) 2008-09-05 2010-03-11 Tiefenbacher Pharmachemikalien Alfred E. Tiefenbacher Gmbh & Co. Kg Partikel aus Ziprasidone und einem Sprengmittel enthaltende Pharmazeutische Zusammensetzung
CA2937222C (en) 2009-06-25 2019-06-04 Alkermes Pharma Ireland Limited Prodrugs of nh-acidic compounds
EP2340834A1 (en) 2009-12-30 2011-07-06 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Enhanced Solubility of Ziprasidone
ES2762113T3 (es) 2010-01-11 2020-05-22 Nalpropion Pharmaceuticals Inc Métodos de proporcionar terapia de pérdida de peso en pacientes con depresión mayor
SI3257500T1 (sl) 2010-02-25 2019-12-31 Bristol-Myers Squibb Holdings Ireland Unlimited Company Formulacije apiksabana
US20130108701A1 (en) 2010-05-25 2013-05-02 Krishna Murthy Bhavanasi Solid Dosage Forms of Antipsychotics
SI23610A (sl) 2011-01-13 2012-07-31 Diagen@d@o@o Nove adicijske soli ziprasidona postopek za njihovo pripravo in njihova uporaba v terapiji
EP4104824A1 (en) 2012-06-06 2022-12-21 Nalpropion Pharmaceuticals LLC Composition for use in a method of treating overweight and obesity in patients with high cardiovascular risk
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
CN112423754A (zh) 2018-03-05 2021-02-26 奥克梅斯制药爱尔兰有限公司 阿立哌唑的给药策略

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5264446A (en) * 1980-09-09 1993-11-23 Bayer Aktiengesellschaft Solid medicament formulations containing nifedipine, and processes for their preparation
MX173362B (es) * 1987-03-02 1994-02-23 Pfizer Compuestos de piperazinil heterociclicos y procedimiento para su preparacion
US4883795A (en) * 1988-01-22 1989-11-28 Pfizer Inc. Piperazinyl-heterocyclic compounds
US4831031A (en) * 1988-01-22 1989-05-16 Pfizer Inc. Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
DE4141268A1 (de) * 1991-12-14 1993-06-17 Merck Patent Gmbh Pharmazeutische zubereitung
US5338846A (en) * 1992-08-26 1994-08-16 Pfizer Inc. Process for preparing aryl piperazinyl-heterocyclic compounds with a piperazine salt
US5206366A (en) * 1992-08-26 1993-04-27 Pfizer Inc. Process for preparing aryl piperazinyl-heterocyclic compounds
US5312925A (en) * 1992-09-01 1994-05-17 Pfizer Inc. Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride
US5359068A (en) * 1993-06-28 1994-10-25 Pfizer Inc. Processes and intermediates for the preparation of 5-[2-(4-(benzoisothiazol-3-yl)-piperazin-1-yl)ethyl]-6-chloro-1,3-dihydro-indol-2-one
DK0790236T3 (da) * 1996-02-13 2004-02-23 Pfizer Prolægemidler af 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chlor-1,3-dihydro-2H-indol-2-on
EP0901786B1 (en) * 1997-08-11 2007-06-13 Pfizer Products Inc. Solid pharmaceutical dispersions with enhanced bioavailability

Also Published As

Publication number Publication date
KR100338915B1 (ko) 2002-05-30
US6150366A (en) 2000-11-21
OA11064A (en) 2002-03-13
CZ212799A3 (cs) 2000-09-13
PL333737A1 (en) 1999-12-20
PE20000632A1 (es) 2000-07-26
IL130424A (en) 2003-10-31
DE69908021D1 (de) 2003-06-26
AP1216A (en) 2003-10-19
EA199900467A3 (ru) 2000-04-24
HRP990193B1 (en) 2003-08-31
RS49611B (sr) 2007-06-04
EA199900467A2 (ru) 1999-12-29
MA26647A1 (fr) 2004-12-20
NO316713B1 (no) 2004-04-13
SK76999A3 (en) 2000-12-11
AU3398399A (en) 1999-12-23
TW590774B (en) 2004-06-11
PL195209B1 (pl) 2007-08-31
SK286245B6 (sk) 2008-06-06
JP4187423B2 (ja) 2008-11-26
HUP9901960A3 (en) 2000-09-28
HK1024184A1 (en) 2000-10-05
IS5079A (is) 1999-12-16
IL130424A0 (en) 2000-06-01
SI0965343T1 (en) 2003-10-31
AP9901579A0 (en) 1999-06-30
DK0965343T3 (da) 2003-08-04
AU753820B2 (en) 2002-10-31
HUP9901960A2 (hu) 2000-08-28
EA002223B1 (ru) 2002-02-28
IS2182B (is) 2006-12-15
HU226487B1 (en) 2009-03-02
JP2000007566A (ja) 2000-01-11
BG64691B1 (bg) 2005-12-30
CN1307994C (zh) 2007-04-04
HU9901960D0 (en) 1999-08-30
ES2197581T3 (es) 2004-01-01
EP0965343B1 (en) 2003-05-21
ID23546A (id) 2000-05-04
YU27199A (sh) 2002-12-10
HN1999000089A (es) 1999-11-03
CY2003002I1 (el) 2009-11-04
PT965343E (pt) 2003-08-29
SG77243A1 (en) 2000-12-19
JP3441676B2 (ja) 2003-09-02
BG103489A (en) 2000-07-31
HRP990193A2 (en) 2000-02-29
KR20000006143A (ko) 2000-01-25
UA59383C2 (uk) 2003-09-15
AR015553A1 (es) 2001-05-02
GT199900080A (es) 2000-11-29
BR9902268A (pt) 2000-05-02
CA2274338C (en) 2003-04-15
CZ297954B6 (cs) 2007-05-09
CA2274338A1 (en) 1999-12-15
ZA993938B (en) 2000-12-14
EP0965343A2 (en) 1999-12-22
JP2002003492A (ja) 2002-01-09
EP0965343A3 (en) 2000-02-23
NZ336271A (en) 2000-10-27
NO992892D0 (no) 1999-06-14
TR199901379A2 (xx) 2000-01-21
DE69908021T2 (de) 2003-11-27
UY25649A1 (es) 2000-02-23
ATE240732T1 (de) 2003-06-15
CN1242987A (zh) 2000-02-02
PA8475601A1 (es) 2000-09-29
MY121397A (en) 2006-01-28
PL195606B1 (pl) 2007-10-31
NO992892L (no) 1999-12-16

Similar Documents

Publication Publication Date Title
CO5070579A1 (es) Formulaciones de ziprasidona
CO5271657A1 (es) Derivados de azaindol
GEP20053614B (en) Compositions for Oral Administration Containing Opioid Agonist
MXPA04003009A (es) Champu que contiene un polimero cationico y particulas.
CO5140093A1 (es) Epotilonas c 21 modificadas
PT1204654E (pt) Benzofurilpiperazinas agonistas do receptor 5-ht2c da serotonina
AU2002213336A1 (en) Substituted heterocyclic compounds for treating multidrug resistance
WO2003105793A3 (en) COMPOSITION CONTAINING CATIONIC POLYMER HAVING HIGH LOAD DENSITY AND HAIR TONERING AGENT
CO5221115A1 (es) Nuevos compuestos fungicidas
ES2191616T3 (es) Polvos pulverizables de fluoropolimeros no fibrilables.
CO5420196A1 (es) Compuestos inhibidores de metaloproteasa bidentes, composi- ciones farmaceuticas que los contienne y metodos para su utilizacion
CO5251405A1 (es) 2-(3,5-bis-trifluorometil-fenil)-n-metil-n-(6-morfolin-4-il- 4-o-tolil-piridin-3-il)-isobutiramida
SE0100822D0 (sv) Method II to obtain microparticles
EP1594571A4 (en) MICROPARTICLES FOR SELECTIVE TARGET HYPERTHERMIA
MX262326B (es) Composiciones cosmeticas que comprenden copolimeros de acido metacrilico, particulas minerales insolubles y polimero cationico y sus utilizaciones.
CO5090837A1 (es) Derivados de 1,3,4-oxadiazolona
DK1204659T3 (da) Serotonerge benzofuraner
ATE280169T1 (de) Serotonerge benzothiophene
CO5140099A1 (es) Ciertas caprolactamas sustituidas, composiciones farmaceuticas que las contienen, y su uso en el tratamiento de tumores
ECSP993015A (es) Formulaciones de ziprasidona
AU3630297A (en) Galanin
IT1317305B1 (it) Dispositivo di regolazione e bloccaggio di due parti mobilmenteaccoppiate l&#39;una all&#39;altra, particolarmente per talloniere, tacchi di
GB0016052D0 (en) Ruthenium (II) compounds
GB0011071D0 (en) Organic compounds
NZ517872A (en) Multidrug efflux pumps